查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1991490

全球抗真菌藥物市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Antifungal Drugs Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 234 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計抗真菌藥物市場將從 2025 年的 216.7 億美元成長到 2034 年的 310.9 億美元，2026 年至 2034 年的複合年成長率為 4.09%。

隨著全球真菌感染疾病發病率的不斷上升，全球抗真菌藥物市場也穩步成長。抗真菌藥物用於治療影響皮膚、指甲、肺部和身體其他部位的真菌感染疾病。這些藥物在治療念珠菌症、麴菌症和其他真菌性疾病方面發揮著至關重要的作用。

市場成長主要受免疫力受損患者數量增加的推動，這些患者更容易感染疾病真菌。接受化療、器官移植或長期抗生素治療的患者通常需要抗真菌藥物治療。人們對真菌感染疾病的認知不斷提高以及診斷能力的進步也促進了抗真菌藥物需求的成長。

抗真菌藥物市場前景依然光明，主要得益於藥物研發不斷推進，促使更有效的治療方法不斷湧現。製劑的改進和聯合治療的進步有望提升治療效果並降低抗藥性。醫療保健覆蓋範圍的擴大和感染控制措施的加強也有望推動市場成長。隨著全球醫療保健系統在應對感染疾病日益高效，抗真菌藥物將繼續發揮至關重要的作用。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球抗真菌藥物市場：依藥物類別分類

  • 市場分析、洞察與預測
  • Azole
  • 棘白菌素類
  • Polyenes
  • Allylamines
  • 其他藥物類別

第5章 全球抗真菌藥物市場：依適應症分類

  • 市場分析、洞察與預測
  • 皮膚絲狀菌症
  • 麴菌症
  • 念珠菌症
  • 白黴菌症
  • 其他跡象

第6章 全球抗真菌藥物市場：依感染疾病類型分類

  • 市場分析、洞察與預測
  • 全身性真菌感染疾病
  • 表層抗真菌感染疾病

第7章 全球抗真菌藥物市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 外用
  • 注射藥物

第8章 全球抗真菌藥物市場：依藥物分類

  • 市場分析、洞察與預測
  • 處方箋
  • OTC

第9章 全球抗真菌藥物市場：按類型分類

  • 市場分析、洞察與預測
  • 品牌商品
  • 非專利的

第10章 全球抗真菌藥物市場：依分銷管道分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第11章 全球抗真菌藥物市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第12章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第13章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Abbott Laboratories
    • Astellas Pharma Inc
    • Bayer AG
    • Enzon Pharmaceuticals Inc
    • GlaxoSmithKline Plc
    • Glenmark Pharmaceuticals Ltd
    • Merck & Co. Inc
    • Novartis AG
    • Pfizer Inc
    • Sanofi SA
簡介目錄
Product Code: VMR11214197

The Antifungal Drugs Market size is expected to reach USD 31.09 Billion in 2034 from USD 21.67 Billion (2025) growing at a CAGR of 4.09% during 2026-2034.

The global antifungal drugs market has grown steadily due to the increasing incidence of fungal infections worldwide. Antifungal drugs are used to treat infections caused by fungi that affect the skin, nails, lungs, and other parts of the body. These medications play an essential role in treating conditions such as candidiasis, aspergillosis, and other fungal diseases.

Market growth is driven by the rising number of patients with weakened immune systems who are more susceptible to fungal infections. Individuals undergoing chemotherapy, organ transplantation, or long-term antibiotic therapy often require antifungal treatments. Increasing awareness about fungal infections and improved diagnostic capabilities have also contributed to greater demand for antifungal medications.

The future outlook for the antifungal drugs market remains positive as pharmaceutical research continues to develop more effective treatment options. Advances in drug formulations and combination therapies may improve treatment outcomes and reduce resistance. Expanding healthcare access and improved infection control practices are expected to support market growth. As global healthcare systems address infectious diseases more effectively, antifungal drugs will remain an important therapeutic category.

MARKET SEGMENTATION

By Drug Class

  • Azoles
  • Echinocandins
  • Polyenes
  • Allylamines
  • Other Drug Classes

By Indication

  • Dermatophytosis
  • Aspergillosis
  • Candidiasis
  • Mucormycosis
  • Other Indications

By Infection Type

  • Systemic Antifungal Infections
  • Superficial Antifungal Infections

By Route of Administration

  • Oral
  • Topical
  • Injectable

By Medication

  • Prescription
  • OTC

By Type

  • Branded
  • Generic

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • Abbott Laboratories, Astellas Pharma Inc, Bayer AG, Enzon Pharmaceuticals Inc, GlaxoSmithKline plc, Glenmark Pharmaceuticals Ltd, Merck Co Inc, Novartis AG, Pfizer Inc, Sanofi SA
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTIFUNGAL DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drug Class
  • 4.2. Azoles Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Echinocandins Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Polyenes Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Allylamines Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTIFUNGAL DRUGS MARKET: BY INDICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Indication
  • 5.2. Dermatophytosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Aspergillosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Candidiasis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Mucormycosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Other Indications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTIFUNGAL DRUGS MARKET: BY INFECTION TYPE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Infection Type
  • 6.2. Systemic Antifungal Infections Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Superficial Antifungal Infections Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTIFUNGAL DRUGS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Route Of Administration
  • 7.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANTIFUNGAL DRUGS MARKET: BY MEDICATION 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast Medication
  • 8.2. Prescription Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. OTC Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ANTIFUNGAL DRUGS MARKET: BY TYPE 2022-2034 (USD MN)

  • 9.1. Market Analysis, Insights and Forecast Type
  • 9.2. Branded Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 9.3. Generic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL ANTIFUNGAL DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 10.1. Market Analysis, Insights and Forecast Distribution Channel
  • 10.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 10.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 10.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 11. GLOBAL ANTIFUNGAL DRUGS MARKET: BY REGION 2022-2034 (USD MN)

  • 11.1. Regional Outlook
  • 11.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 11.2.1 By Drug Class
    • 11.2.2 By Indication
    • 11.2.3 By Infection Type
    • 11.2.4 By Route Of Administration
    • 11.2.5 By Medication
    • 11.2.6 By Type
    • 11.2.7 By Distribution Channel
    • 11.2.8 United States
    • 11.2.9 Canada
    • 11.2.10 Mexico
  • 11.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 11.3.1 By Drug Class
    • 11.3.2 By Indication
    • 11.3.3 By Infection Type
    • 11.3.4 By Route Of Administration
    • 11.3.5 By Medication
    • 11.3.6 By Type
    • 11.3.7 By Distribution Channel
    • 11.3.8 United Kingdom
    • 11.3.9 France
    • 11.3.10 Germany
    • 11.3.11 Italy
    • 11.3.12 Russia
    • 11.3.13 Rest Of Europe
  • 11.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 11.4.1 By Drug Class
    • 11.4.2 By Indication
    • 11.4.3 By Infection Type
    • 11.4.4 By Route Of Administration
    • 11.4.5 By Medication
    • 11.4.6 By Type
    • 11.4.7 By Distribution Channel
    • 11.4.8 India
    • 11.4.9 Japan
    • 11.4.10 South Korea
    • 11.4.11 Australia
    • 11.4.12 South East Asia
    • 11.4.13 Rest Of Asia Pacific
  • 11.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 11.5.1 By Drug Class
    • 11.5.2 By Indication
    • 11.5.3 By Infection Type
    • 11.5.4 By Route Of Administration
    • 11.5.5 By Medication
    • 11.5.6 By Type
    • 11.5.7 By Distribution Channel
    • 11.5.8 Brazil
    • 11.5.9 Argentina
    • 11.5.10 Peru
    • 11.5.11 Chile
    • 11.5.12 Rest of Latin America
  • 11.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 11.6.1 By Drug Class
    • 11.6.2 By Indication
    • 11.6.3 By Infection Type
    • 11.6.4 By Route Of Administration
    • 11.6.5 By Medication
    • 11.6.6 By Type
    • 11.6.7 By Distribution Channel
    • 11.6.8 Saudi Arabia
    • 11.6.9 UAE
    • 11.6.10 Israel
    • 11.6.11 South Africa
    • 11.6.12 Rest of the Middle East And Africa

Chapter 12. COMPETITIVE LANDSCAPE

  • 12.1. Recent Developments
  • 12.2. Company Categorization
  • 12.3. Supply Chain & Channel Partners (based on availability)
  • 12.4. Market Share & Positioning Analysis (based on availability)
  • 12.5. Vendor Landscape (based on availability)
  • 12.6. Strategy Mapping

Chapter 13. COMPANY PROFILES OF GLOBAL ANTIFUNGAL DRUGS INDUSTRY

  • 13.1. Top Companies Market Share Analysis
  • 13.2. Company Profiles
    • 13.2.1 Abbott Laboratories
    • 13.2.2 Astellas Pharma Inc
    • 13.2.3 Bayer AG
    • 13.2.4 Enzon Pharmaceuticals Inc
    • 13.2.5 GlaxoSmithKline Plc
    • 13.2.6 Glenmark Pharmaceuticals Ltd
    • 13.2.7 Merck & Co. Inc
    • 13.2.8 Novartis AG
    • 13.2.9 Pfizer Inc
    • 13.2.10 Sanofi S.A